The financial reports of multinational pharmaceutical companies have been released one after another, and the revenue of many companies in China has exceeded 16 billion yuan

 Recently, multinational pharmaceutical companies have successively released their 2021 financial reports.
According to incomplete statistics, since Johnson & Johnson released its 2021 financial report on January 25, at least 15 multinational pharmaceutical companies have disclosed their performance
.
According to these annual reports, the Chinese market still provides important opportunities for many multinational pharmaceutical companies
.
AstraZeneca Recently, AstraZeneca announced its 2021 financial report, total revenue increased by 41% year-on-year to $37.
417 billion, and net profit attributable to the parent company fell by 96.
50% year-on-year to $112 million
.
Among them, AstraZeneca's revenue in China reached 6.
011 billion US dollars
.
Analysts said that AstraZeneca's several innovative drugs performed outstandingly: the oncology drugs olaparib, durvalumab and osimertinib's revenue growth in emerging markets reached 41%, 68% and 6% respectively, while China's medical insurance policy is an important driving force behind it
.
According to the 2021 annual report released by Merck, the company's revenue in 2021 will increase by 17% year-on-year to $48.
704 billion
.
Among them, the pharmaceutical business revenue increased by 17% year-on-year to $42.
754 billion; animal health revenue increased by 18% year-on-year to $5.
568 billion; K drug revenue was $17.
2 billion, and cervical cancer vaccines also contributed significantly to revenue
.
In addition, Merck China's total revenue increased by 60% year-on-year to US$4.
262 billion, making it the best-performing region for Merck in 2021
.
Roche According to Roche's recently released 2021 financial report, the company's sales in 2021 will increase by 8% year-on-year to 62.
8 billion Swiss francs (about 68.
3 billion US dollars)
.
Among them, the revenue of the pharmaceutical business increased by 3% year-on-year, and the revenue of the diagnostic business increased by 29% year-on-year; the data shows that Roche's revenue in China in 2021 will increase by 4% year-on-year to US$3.
533 billion, accounting for 7.
3% of Roche's global pharmaceutical business revenue
.
It is understood that Roche currently has 201 new drugs approved for marketing, including trastuzumab, rituximab, capecitabine, bevacizumab, ceftriaxone sodium pertuzumab, etc.

.
Among them, sales of trastuzumab for injection accounted for 22.
51% of sales in hospitals across the country; followed by rituximab injection, accounting for 15.
31%; and capecitabine tablets, accounting for 12.
91%
.
Novartis Recently, Novartis announced its financial report.
The announcement showed that the company's 2021 fiscal year annual report attributable to the parent company's ordinary shareholders' net profit increased by 197.
58% year-on-year to $24.
021 billion; operating income increased by 5.
97% year-on-year to $52.
877 billion
.
Novartis' sales revenue in the Chinese market in 2021 will increase by 18% year-on-year to US$3.
052 billion, accounting for 6% of Novartis' total global revenue
.
Novartis stated in the financial report that the increase in medical insurance has become the main driving force
.
It is reported that Novartis’ leading product, secukinumab, will be included in the national medical insurance list in 2020, and the demand will be released quickly
.
In addition, the sales revenue of Novartis' innovative drug segment in 2021 will increase by 8% year-on-year to US$42 billion, which is currently composed of two units, Novartis Oncology and Novartis Pharmaceuticals
.
Among them, the diseases covered by the pharmaceutical business unit mainly include immunity, blood diseases, skin diseases, ophthalmology, neurological, respiratory, cardiovascular, renal and metabolic diseases and other mature diseases
.
Sanofi According to the 2021 financial report data released by Sanofi, Sanofi's net income in 2021 will increase by 7.
1% year-on-year to 37.
761 billion euros (43 billion US dollars)
.
Among them, Sanofi’s revenue in China in 2021 will increase by 7.
9% year-on-year to 2.
720 billion euros (3.
098 billion U.
S.
dollars), mainly benefiting from the growth of Dupixent and the recovery of Plavix (clopidogrel) from the impact of bulk purchases
.
Novo Nordisk recently announced its financial report.
The announcement showed that the company's 2021 annual report net profit attributable to ordinary shareholders of the parent company increased by 13.
33% year-on-year to 47.
757 billion Danish kroner (about 7.
593 billion US dollars); operating income increased by 10.
91% year-on-year % of DKK 140.
800 billion (approximately $22.
385 billion)
.
Novo Nordisk's performance in China was 16.
019 billion Danish kroner (about 2.
547 billion US dollars), a year-on-year increase of 14%
.
It is reported that with the blessing of medical insurance, the sales of Novo Nordisk's blockbuster hypoglycemic drug liraglutide in China will be 1.
544 billion Danish kroner (about 245 million US dollars, about 1.
6 billion yuan) in 2021.
species increased by as much as 45% year-on-year
.
Another new diabetes drug, semaglutide, was sold for 303 million Danish kroner (about 48 million US dollars, about 300 million yuan) in just over half a year after it was launched, and passed the national medical insurance negotiation last year
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.